Kiniksa Pharmaceuticals International Plc (KNSA): Next-Year EPS Estimate 47.30%
As of 2026-09-11, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 47.30%. Featured in 4 EPS revision reports, most recently on 2026-07-31.
On 2026-08-13, analyst consensus for KNSA's next-year EPS growth shifted from 47.27% to 47.30% — a positive change of 0.03 percentage points. The revised estimate has been sustained across 27 subsequent trading sessions. Current-year growth is projected at 85.70%.
What's Driving This
Kiniksa shares have risen primarily after analysts raised the next-year EPS growth estimate from 39.66% to 47.43% on July 29, 2026, a 7.77 percentage point revision. The upgrade followed Q2 2026 results and a raise to 2026 ARCALYST sales guidance, which plausibly drove the higher earnings outlook. The estimate now stands at 47.30%, indicating momentum has largely held beyond the initial revision.
Generated 2026-09-10 from news as of 2026-09-10
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 47.30%
- EPS growth this year
- 85.70%
- EPS next quarter (est)
- $0.37
- Last price
- $76.75
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-09-11 | 47.30% | 85.70% | $0.37 | $76.75 |
| 2026-09-10 | 47.30% | 85.70% | $0.37 | $76.48 |
| 2026-09-09 | 47.30% | 85.70% | $0.37 | $78.52 |
| 2026-09-08 | 47.30% | 85.70% | $0.37 | $77.09 |
| 2026-09-07 | 47.30% | 85.70% | $0.37 | $77.91 |
| 2026-09-06 | 47.30% | 85.70% | $0.37 | $77.91 |
| 2026-09-04 | 47.30% | 85.70% | $0.37 | $77.91 |
| 2026-09-03 | 47.30% | 85.70% | $0.37 | $80.47 |
| 2026-09-02 | 47.30% | 85.70% | $0.37 | $79.89 |
| 2026-09-01 | 47.30% | 85.70% | $0.37 | $79.28 |
| 2026-08-31 | 47.30% | 85.70% | $0.37 | $78.63 |
| 2026-08-30 | 47.30% | 85.70% | $0.37 | $78.08 |
| 2026-08-29 | 47.30% | 85.70% | $0.37 | $78.08 |
| 2026-08-28 | 47.30% | 85.70% | $0.37 | $78.08 |
| 2026-08-27 | 47.30% | 85.70% | $0.37 | $79.80 |
| 2026-08-26 | 47.30% | 85.70% | $0.37 | $78.68 |
| 2026-08-25 | 47.30% | 85.70% | $0.37 | $80.20 |
| 2026-08-24 | 47.30% | 85.70% | $0.37 | $79.38 |
| 2026-08-23 | 47.30% | 85.70% | $0.37 | $79.03 |
| 2026-08-21 | 47.30% | 85.70% | $0.37 | $79.03 |
| 2026-08-20 | 47.30% | 85.70% | $0.37 | $78.47 |
| 2026-08-19 | 47.30% | 85.70% | $0.37 | $80.80 |
| 2026-08-18 | 47.30% | 85.70% | $0.37 | $79.49 |
| 2026-08-17 | 47.30% | 85.70% | $0.37 | $79.18 |
| 2026-08-16 | 47.30% | 85.70% | $0.37 | $76.75 |
| 2026-08-14 | 47.30% | 85.70% | $0.37 | $76.75 |
| 2026-08-13 | 47.30% | 85.70% | $0.37 | $77.83 |
| 2026-08-12 | 47.27% | 85.74% | $0.37 | $78.15 |
| 2026-08-11 | 47.30% | 85.70% | $0.37 | $77.80 |
| 2026-08-10 | 47.30% | 85.70% | $0.37 | $76.53 |
Reports Featuring KNSA
- 2026-07-31
NDLS +30.7% Leads EPS Revision Gainers; FFAI +28.1% Follows
- 2026-07-30
PMN Jumps 27.3% on EPS Revision and Alzheimer's Trial Data; KNSA, NDLS Follow
- 2026-07-29
KNSA Surges 28% on EPS Revision, Record Revenue; AMC, BZUN, CLF Also Climb
- 2026-07-28
CLF Surges 33.4% After EPS Revision; Steel Sector Leads
Recent News
- Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call SummaryMoby
- Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales GuidanceInvestorsHub
- Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026GlobeNewswire
- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
Screen Performance
Aggregate stats across all 2037 tickers our top-EPS-revision screen has flagged over the past 163 days.
- Median return since detection
- +1.0%
- % of tickers in the green
- 52%
- Median return on winners
- +21.6%
- Large revisions captured
- 1704
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Kiniksa Pharmaceuticals International Plc's next-year EPS growth estimate?▾
As of 2026-09-11, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 47.30%, based on analyst consensus.
When was the latest EPS estimate revision for KNSA?▾
The most recent revision occurred on 2026-08-13, when analysts adjusted the next-year EPS growth estimate from 47.27% to 47.30%.
What sector and industry does Kiniksa Pharmaceuticals International Plc belong to?▾
Kiniksa Pharmaceuticals International Plc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. KNSA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Kiniksa Pharmaceuticals International Plc (KNSA) appears here because it was detected by our daily top-EPS-revision-performer screen.